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Among several strategies used for Herpes simplex virus (HSV) detection in biological
specimens, standard plaque assay (SPA) remains the most reliable method to evaluate
virus infectivity and quantify viral replication. However, it is a manual procedure, thereby
affected by operator subjectivity, and it may be particularly laborious for multiple sample
analysis. Here we describe an innovative method to perform the titration of HSV
type 1 (HSV-1) in different samples, using the “In-Cell WesternTM” Assay (ICW) from
LI-COR, a quantitative immunofluorescence assay that exploits laser-based scanning of
near infrared (NIR). In particular, we employed NIR-immunodetection of viral proteins
to monitor foci of HSV-1 infection in cell monolayers, and exploited an automated
detection of their fluorescence intensity to evaluate virus titre. This innovative method
produced similar and superimposable values compared to SPA, but it is faster and can
be performed in 96 well plate, thus allowing to easily and quickly analyze and quantify
many samples in parallel. These features make our method particularly suitable for the
screening and characterization of antiviral compounds, as we demonstrated by testing
acyclovir (ACV), the main anti-HSV-1 drug. Moreover, we developed a new data analysis
system that allowed to overcome potential bias due to unspecific florescence signals,
thus improving data reproducibility. Overall, our method may represents a useful tool for
both clinical and research purposes.
Keywords: HSV-1, herpes simplex virus, plaque assay, virus titration, near-infrared fluorescence, immunostaining,
antivirals
INTRODUCTION
Herpes simplex viruses (HSV) are enveloped DNA-viruses, causing recurrent infections in different
sites including lips, eyes (especially for HSV type 1, HSV-1) and genital tract (particularly for
HSV type 2, HSV-2). Following a primary infection, they are able to establish a latent infection
in neuronal ganglia that is usually followed by lifelong periodic reactivations. They can also reach
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the central nervous system causing severe forms of encephalitis.
During productive infection, HSV efficiently redirect the
host transcriptional machinery to express their own genes
in a precise regulated temporal cascade, consisting of the
sequential expression of three gene classes: the immediate-early
(IE, including Infected Cell Protein 4, ICP4), early (E) and late
(L, including glycoprotein B, gB) genes (Roizman and Knipe,
2001).
Several strategies are used for HSV detection in biological
specimens. Among these, the amplification of viral specific
genes through polymerase chain reaction (PCR) (Espy et al.,
2000; Van der Beek et al., 2013) allows to check and
eventually quantify the viral DNA, but it does not give specific
information about the replicative efficiency of the virus and its
infectivity.
Alternatively, HSV antigens can be detected by direct
immunofluorescence (IF) assay using fluorescein-labeled
monoclonal antibodies or enzyme immunoassay (Forghani et al.,
1985; Baker et al., 1989; Verano and Michalski, 1990), though
their sensitivity is quite low.
So far, the most reliable method to detect and titrate
HSV in biological samples remains the virus isolation and
quantification by standard plaque assay (SPA). In this method,
a confluent monolayer of permissive cells is incubated with
the biological sample potentially containing HSV, and then
covered with an immobilizing semisolid overlay medium
to prevent indiscriminate spreading of neo-formed virions.
Thus, viral infection and replication are constrained to the
surrounding cells and individual plaques, or zones of cell
death, become detectable and countable. The HSV titre
results from the number of formed plaques per milliliter
of sample, and it is expressed as plaque forming unit per
ml (PFU/ml) (Langlois et al., 1986; Kruppenbacher et al.,
1994).
Standard plaque assay is also used for basic research purposes,
i.e., to check the efficacy of HSV infection in cells by evaluating
the titre of neo-formed virion released in cell supernatants.
Plaque reduction assay (PRA), a SPA variant, is exploited
to determine HSV susceptibility to antiviral drugs, allowing
to calculate the drug concentration able to reduce plaque
formation by 50% (IC50) (Safrin et al., 1994). Although
SPA is a very sensitive and specific method, it may be
particularly laborious and time-consuming for multiple sample
analysis and is affected by operator subjectivity in plaque
counting.
Here we describe an innovative method we set up to
perform HSV-1 titration in different samples, using the “In-
Cell WesternTM” Assay (ICW) from LI-COR, a quantitative IF
assay that utilizes laser-based scanning of near infrared (NIR). In
particular, we employed viral protein infrared-immunodetection
to monitor foci of HSV-1 infection in cell monolayer. This
innovative technique produced similar and superimposable
values compared to SPA. Moreover, by using ICW to evaluate the
IC50 of Acyclovir (ACV), the main anti-HSV-1 drug, we provided
evidence demonstrating that this method is suitable for the
screening of antiviral compounds, showing several advantages
compared to both SPA and PRA. Furthermore, by exploiting




African green monkey kidney (Vero) cells were grown in RPMI
1640 medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1% glutamine, 50 U per ml penicillin,
and 50 µg/ml streptomycin. All reagents were purchased by
Sigma–Aldrich, St. Louis, MO, United States. The cells were
maintained at 37◦C in humidified air containing 5% CO2.
Virus production was performed as previously reported
(De Chiara et al., 2016). Briefly, monolayers of Vero cells in
75-cm2 tissue culture flasks were infected with HSV-1 strain F
(according to appropriate guidelines for the use and handling
of BSL-2 pathogenic microorganisms as HSV-1) (Burnett et al.,
2009) at a multiplicity of infection (m.o.i.) of 0.01. After
48 h at 37◦C, HSV-1 infected cells were harvested with 3
freeze-and-thaw cycles, and cellular debris were removed with
low-speed centrifugation, and the supernatant was stored at
−80◦C, until used. Virus titer in the supernatant was measured
by conventional SPA (Killington and Powell, 1991). The titer of
the virus preparation was 5× 107 PFU/ml.
HSV-1 Staining Using ICW
Vero cells were seeded in 96 well plate and grown to 90%
confluency for 24 h. Then, cells were infected with serial dilutions
of HSV-1 in RPMI, or supernatants from HSV-1-infected cells.
After 1 h of incubation at 37◦C, supernatants were aspirated,
cells washed two times with PBS, and then incubated with 2%
FBS-RPMI for 24 h at 37C◦ in 5% CO2 in the presence or absence
of ACV. ACV dilutions were prepared as described (Sarisky et al.,
2001; Civitelli et al., 2014). Cells were washed with PBS twice
and fixed with 50 µl of 4% paraformaldehyde in PBS for 15 min
at room temperature (rt), and then were permeabilized in 0.1%
triton X-100 PBS for 5 min at rt. Following the incubation with
Odyssey Blocking Buffer for 1 h at rt, cells were incubated with
anti-glycoprotein B (gB) or anti-ICP4 antibodies (sc-56987 and
sc-S9808N, Santa Cruz, respectively, 1:1000 dilution in Odyssey
Blocking buffer) for 1 h and then washed three times with
PBS containing 0.1% Tween-20. Afterward, labeled secondary
antibody IRDye 800 CW Goat Anti Mouse (926-32210 LI-COR
Biosciences, 1:1000 dilution in Odyssey Blocking buffer) and
CellTag 700 Stain (926-41090, LI-COR Biosciences, 1:500) were
added to each well, and after 1 h, cells were washed four times
with PBS containing 0.1% Tween-20. Finally, the plate was
scanned on the Odyssey Infrared Imager, and the integrated
intensity value of each well read by LI-COR Image Studio
Software developed for Odyssey analysis.
HSV-1 Titre Evaluation by ICW
LI-COR Image Studio Software, developed for Odyssey analysis,
was used to acquire the integrated fluorescence intensity from
each well. To evaluate virus titre, a standard curve was performed
for each experiment by infecting Vero cells with 10-fold serial
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dilutions of virus stock (stock titre: 5 × 107 PFU/ml), and using
mock-infected wells to assess fluorescence intensity background.
Standard curves were built by plotting integrated fluorescence
intensity (a.u.) measured for each virus dilution versus its relative
viral titre expressed as log PFU/ml, and exhibit a sigmoidal
or S-shaped trend. HSV-1 titre in unknown samples (i.e.,
supernatans from HSV-1 infected cells and HSV-1 infection in
the presence of ACV) was interpolate from standard curve using
the mathematical model four-parameter logistic-log (Sigmoidal
4PL) in GraphPad Prism v6 (GraphPad Software, Inc.).
HSV-1 Plaque Assay
Different 10-fold dilutions of HSV-1-containing samples were
incubated on monolayers of Vero cells (24 well plate) at 37◦C
for 1 h to allow the virus to attach and entry into cells. Then
supernatants were aspirated, cells washed two times with PBS,
and incubated with 2% carboxymethyl-cellulose (CMC) in 2%
FBS-RPMI for 3 days at 37◦C in 5% CO2 to allow plaque
formation. For plaque counting, the cells were fixed with ice-cold
100% methanol for 20 min at −20◦C and stained with 0.5%
crystal violet in 10% ethanol for 10 min. HSV-1 titre was
calculated through plaque counting and expressed as PFU/ml. All
the reagents were purchased from Sigma–Aldrich.
Data Analysis System
A data analysis system was developed by exploiting a Java-
based image processing program (IMAGE-J), that allows to
identify the surface area occupied by fluorescence in each
well and to calculate from this the output parameter ‘area
percentage,’ i.e., the percentage of well area covered by
fluorescence (Guzman et al., 2014). For this evaluation, the
image obtained by Odyssey Software was converted in a single
8-bit grayscale image for each fluorescence channel. In 8-bit
greyscale images there are 256 intensity graduations where the
intensity is zero for pixels that do not contain fluorescence
and a number between 1 and 255 for pixels containing
fluorescence.
By using the command “Image → Adjust → Threshold”
specific threshold lines were set for each experiment to select
pixels falling within a specified range. In particular, the
integrated intensity from uninfected cells was used to set the
lowest threshold value, whereas integrated intensity values from
unspecific fluorescence peaks were used to set the maximum
threshold. Thus, the selected specific signals between these
threshold lines were used to calculate the ‘area percentage’
covered by fluorescence for each well. The resulting values were
fitted by a non-linear regression using the mathematical model
log (inhibitor) vs. normalized response in GraphPad Prism v6
(GraphPad Software, Inc.) to determine ACV IC50.
RESULTS
ICW Is a Suitable Technique to Detect
HSV-1 Infection in Cells
To check whether ICW is a suitable technique to monitor
HSV-1 infection, we performed a pilot experiment by infecting
Vero cells with serial dilutions of the virus, starting from
5 × 105 PFU/ml. The cells were fixed 24 h p.i. and then
stained with anti-gB and with the appropriate NIR-secondary
antibody, followed by scanning on the Odyssey Infrared Imager.
Mock-infected cells were used as controls to evaluate the
threshold of autofluorescence background. In parallel, the same
HSV-1 dilutions were also titrated by SPA. Results in Figure 1A
show that fluorescence intensity from HSV-1-infected cells grew
with virus challenge (PFU/ml), indicating that ICW technique
could monitor virus infection. Moreover, gB staining resulted
in foci of infection, whose morphology (see also inset in
panel A) was comparable to those evidenced by SPA (Figure 1B),
indicating that gB protein expression is a suitable marker to
quantify neo-virion production. Thus, we used for the following
experiments gB staining to detect/quantify HSV-1 infection.
ICW Technique vs. Standard Plaque
Method
To evaluate whether ICW technique may be exploited for
HSV-1 titration in biological samples, we used this method in
comparison with SPA to quantify virus titre in two supernatants
from HSV-1-infected cells (HSV-1-SA and HSV-1-SB). First,
serial dilutions of HSV-1 with a known titre were tested by ICW
on Vero cells plated in 96 wells to build up the standard curve
with the relative fluorescence intensity values (Figure 2A). On
the same plate, three dilutions of each sample were tested in
duplicate (Figure 2B) and their HSV-1 titre was calculated by
interpolating their fluorescence values on the standard curve,
resulting in 1.2 × 106 ± 5.2 × 105 PFU/ml (HSV-1-SA) and
1.3 × 104 ± 2.8 × 103 PFU/ml (HSV-1-SB). In parallel,
viral titres were measured by SPA (Figure 2C) resulting in
7.6× 105 PFU/ml and 2.0× 104 ± 7× 103 PFU/ml for HSV-1SA
and HSV-1SB, respectively. Thus, virus titre calculated with ICW
was almost completely superimposable to that resulting from
SPA (Figure 2D). We also evaluated HSV-1 titre by counting
the number of gB-detected HSV-1 foci (FFU), obtaining similar
results (Figure 2D). It is noteworthy that in our hands ICW
was more suitable than SPA for these titrations, especially for
1:10/1:100 dilutions that resulted in too high and uncountable
number of plaques in SPA. These results demonstrate that ICW
technique using “Odyssey R© CLx Imaging System” is an accurate
and fast method for HSV-1 titration that requires a lower number
of cells and sample-dilutions with respect to SPA.
ICW Technique for Antiviral Drug
Screening
To evaluate whether ICW method may be exploited for the
screening of anti-HSV-1 drugs, we tested virus titre in Vero cells
infected in the presence of ACV, the main inhibitor of HSV-
1 replication (Elion, 1982). Vero cells seeded in 96 wells were
infected with HSV-1 at different m.o.i. (0.1, 0.5, and 1) and
treated with serial concentrations of ACV ranging from 0.0005
to 1 µg/ml. Twenty-four hour later, cells were fixed and stained
with antibodies raised against ICP4 or gB, early and late viral
proteins, respectively (green fluorescence, Figure 3A). In this
set of experiments, cells were also stained with Cell-Tag 700, a
Frontiers in Microbiology | www.frontiersin.org 3 June 2017 | Volume 8 | Article 1085
fmicb-08-01085 June 13, 2017 Time: 17:16 # 4
Fabiani et al. Change to H9N2 AIV with NS1 Truncations
FIGURE 1 | “In-Cell WesternTM” Assay is a suitable technique to detect HSV-1 infection in cells. (A) Vero cells were seeded in 96 wells and infected with the
indicated 10-fold serial dilutions of HSV-1. 24 h p.i. cells were fixed and immunostained with anti-gB antibody, followed by incubation with IRDye 800CW goat
anti-mouse antibody, and relative fluorescence detected with LI-COR Odyssey Infrared Imaging System. A representative image of one of the three experiments
performed is shown, with a close up image of HSV-1 foci of infection (inset) and the relative standard curve built up with the mean value of fluorescence intensity
(arbitrary unit, a.u.) detected for each experimental point. (B) Representative image of SPA performed with the same HSV-1 dilutions used in (A).
fluorescent dye that stains cells and allows to detect cell layer
(red fluorescence in Figure 3A), in order to normalize viral
protein fluorescence intensity to cell number. Mock-infected cells
were used as controls, and their intensity used as background.
Normalized fluorescence intensity resulting from each staining
was used to evaluate viral replication. Figure 3B shows the
percentage (%) of viral replication measured in cells infected
in the presence of different ACV concentrations versus those
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FIGURE 2 | “In-Cell WesternTM” Assay vs. standard plaque assay. (A) ICW Internal standard curve built up by using the mean value of intensity fluorescence
detected in Vero cells infected with 10-fold serial dilutions of HSV-1 with a known titre. (B,C) Two unknown HSV-1 samples (HSV-1-SA and HSV-1-SB) were titrated
using ICW (B) and SPA (C) as described in Section “Materials and Methods.” (D) Mean values of HSV-1-SA and HSV-1-SB titer for each tested dilution in the two
assays. N.D. = not detectable; U = uncountable.
measured in HSV-1-infected cells (100%). ACV IC50 was
calculated from each staining (ICP4: upper graph; gB: lower
graph), obtaining similar values (0.031 µg/ml for ICP4 staining
vs. 0.022 µg/ml for gB staining). The slight discrepancy may be
due to unspecific fluorescence peaks observed for each staining
(see inset and arrows in Figure 3A).
To avoid these random acquisition troubles, we developed
a new and innovative data analysis system, by exploiting a
Java-based image processing program (IMAGE-J) that allowed
to normalize for each well the fraction-area covered by green
fluorescence to total area. In particular, unspecific fluorescence
peaks were excluded from the selected fraction-area by using
specific threshold lines. Normalized fraction area was used
to calculate viral replication in each well. The IC50 for
ACV was calculated from graphs in Figure 3C, resulting in
superimposable values (0.018 µg/ml for ICP4 staining, upper
graph, 0.025 µg/ml for gB, lower graph). These results were
also compared to those obtained through a parallel PRA assay,
performed using the same ACV concentrations to treat Vero cells
following HSV-1-infection at 0.1 m.o.i.. We found similar results
(0.03< IC50< 0.07 µg/ml, Supplementary Figure S1)
Overall, these results strongly support ICW as suitable
technique for HSV-1 titration in biological samples and antiviral
drug screening.
DISCUSSION
Herein, we describe an innovative method for HSV-1 titration,
which allows to easily and quickly analyze viral replication and
infectivity in many samples in parallel. Thanks to these features,
it is particularly suitable in experimental virology and especially
for the screening of antiviral compounds. Moreover, this method
shows a greater flexibility than standard SPA, since it can be
exploited for different viruses causing or not cytopathic effects
(CPE) (Counihan et al., 2006; Weldon et al., 2010; Kumar et al.,
2012).
Until now, SPA was considered the most accurate method
for the direct quantification of infectious virions, including
HSV-1, as well as for screening of antiviral compounds (as
PRA). This method is based on the counting of discrete plaques
caused by virus-induced CPE, considered a marker of infectious
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FIGURE 3 | “In-Cell WesternTM” Assay is a suitable technique for antiviral screening. (A) HSV-1 infected Vero cells (with the indicated m.o.i.) were treated for 24 h
with concentrations of ACV ranging from 0.0005 to 1 µg/ml. Fixed cells were incubated with anti-gB or anti-ICP4 antibodies and then stained with IRDye 800 CW
(green fluorescence) and CellTag 700 Stain (red fluorescence). Arrows highlight unspecific fluorescence peaks (a close up view in the inset). (B,C) Representative
dose-response curves of ACV activity on HSV-1 replication (shown as percentage of virus replication in ACV treated cells vs. untreated ones) using LI-COR Image
Studio Software (B) or Image-J (C) for data analysis. ACV IC50 was calculated from each staining and the mean values resulted from experiments performed with
different m.o.i. of virus are reported (0.031 µg/ml for ICP4 staining, 0.022 µg/ml for gB staining using LI-COR Image Studio Software; 0.018 µg/ml for ICP4 staining,
0.025 µg/ml for gB staining using Image-J software).
viral units. Unfortunately, it is time consuming (e.g., 48–72 h
for HSV-1), especially because virus-induced CPE may take a
long time to be visualized as plaques. Moreover, it generally
needs high volume of samples (70–700 µl to be analyzed on
cell seeded in 24 well plate) and the results may be affected
by several technical problems, such those related to the cells
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susceptibility or to cell overlay systems (Borisevich et al.,
2007; Baer and Kehn-Hall, 2014) and potential human bias
introduced by manual plaque counting. Recently Tardif et al.
(2014) developed a chemiluminescence assay that allows to
detect viral CPE indirectly (through measuring ATP-dependent
chemiluminescence after the addition of a specific luminescent
compound). This assay, by taking advantages of an automated
chemiluminescence plate reader, overcomes SPA subjectivity of
plaque counting, but shows some drawbacks, including a quite
long experimental time (7 days) to obtain results. In addition both
this method and SPA can be preferentially used for viruses able to
induce CPE in cells.
On the contrary, our method allows a quicker detection of
HSV-1 infectious foci (e.g., 24 h for HSV-1), does not need the
use of cell overlay systems, requires a smaller volume of samples
(12–120 µl in 96 well seeded cells – thus also taking advantage of
multichannel pipettor use for handling large amount of samples),
and provides an easily automated readout of the results by the aid
of Odyssey instrumentation, thus increasing data reproducibility.
Differently to SPA, ICW requires an internal standard curve
for each experiment. This may represent a limit. However,
especially for basic research purposes, the use of internal HSV-1
standard allows to check the infectivity of the virus stock for each
experiment and, at the same time, to easily compare experiments
performed under different conditions (time p.i., m.o.i., etc).
Moreover, ICW recommends the use of a CellTag to normalize
specific virus IF to cell number in the analyzed monolayer: this
allows to overcome some technical troubles of SPA, especially
those related to partial disruption of cell layer by high rate
of virus infection and/or an high/diffuse and uncountable
number of plaques (see for example Figure 2C). Similarly,
fluorescence normalization allows ICW to easily detect foci of
infection at the lowest sample concentration, up to single infected
cells. At the same time, as reported by Weldon et al. (2010),
NIR detection method provides a reduced autofluorescence
background from biological molecules and limited light scatter
than other visual IF assay, thus limiting potential bias in data
interpretation and improving the assay sensitivity. By exploiting
IMAGE-J software for avoiding unspecific fluorescence peaks,
we further improve data analysis and interpretation of the
results. On the other hand, ICW detection limit at the highest
dilutions (e.g., 1:1000 dilution in Figure 2B) may be affected
by the lower sample volume required by this assay with
respect to SPA (50 µl vs. 300 µl), and by the different
endpoints (24 h p.i. for ICW vs. 48–72 h p.i. for SPA). This
means that in ICW a smaller number of viral particles are
allowed to infect cells for a shorter time. In addition, the
reagent sensitivity (especially primary antibodies against viral
proteins) may play a role in virus detection. It is noteworthy
to mention that ICW, by exploiting commercial antibodies
that are able to recognize HSV-1 proteins, may be generally
used for a wide range of virus strains. Eventual differences
in protein expression among strains should not affect virus
titre determination, since the method is based on an internal
standard curve performed for each experiment with the same
virus strain.
Beyond PRA, other methods have been so far developed for
a rapid screening of antiherpetic compounds. They are mainly
based on reporter systems such as luciferase and/or fluorescent
proteins and are aimed at identifying antivirals targeting the
early steps of HSV infection (Zhu et al., 2010; Matza-Porges
et al., 2014; Maeda et al., 2016). These methods generally require
the use of reporter-expressing recombinant viruses or cell lines
transfected to express a reporter protein under a specific viral
promoter. As we demonstrated for ACV (Figure 3), ICW and our
modifications, by exploiting wild type HSV-1 strains and Vero
cells, can be applied for the screening of antiviral drugs. In this
view, the possibility to detect different viral proteins (e.g., gB and
ICP4 as we demonstrated for HSV-1) makes ICW particularly
suitable even for the characterization of different steps of viral
replication and to explore the mechanisms of action of antiviral
drugs, including those targeting early steps of the infection.
Overall, these advantageous features makes ICW a useful tool
for virologists.
AUTHOR CONTRIBUTIONS
GDC and MEM designed the experiments. MF, DL, and MEM
performed the experiments. MF, ATP, GDC, and MEM analyzed
the data. MF, ATP, GDC, and MEM wrote the manuscript.
FUNDING
This work was supported by grant from the Italian
Ministry of Instruction, University and Research (PRIN-
PRIN2015W729WH) to ATP and to GDC, and by Regione Lazio
(FILAS cup B88C14000500002) to ATP.
SUPPLEMENTARY MATERIAL




Baer, A., and Kehn-Hall, K. (2014). Viral concentration determination through
plaque assays: using traditional and novel overlay systems. J. Vis. Exp. 93:52065.
doi: 10.3791/52065
Baker, D. A., Gonik, B., Milch, P. O., Berkowitz, A., Lipson, S., and Verma, U.
(1989). Clinical evaluation of a new herpes simplex virus ELISA: a rapid
diagnostic test for herpes simplex virus. Obstet. Gynecol. 73(3 Pt 1), 322–325.
doi: 10.1016/0020-7292(89)90375-5
Borisevich, V., Nistler, R., Hudman, D., Yamshchikov, G.,
Seregin, A., and Yamshchikov, V. (2007). A highly sensitive and
versatile virus titration assay in the 96-well microplate forma.
J. Virol. Methods 147, 197–205. doi: 10.1016/j.jviromet.2007.
08.015
Frontiers in Microbiology | www.frontiersin.org 7 June 2017 | Volume 8 | Article 1085
fmicb-08-01085 June 13, 2017 Time: 17:16 # 8
Fabiani et al. Change to H9N2 AIV with NS1 Truncations
Burnett, L. C., Lunn, G., and Coico, R. (2009). Biosafety: guidelines for working
with pathogenic and infectious microorganisms. Curr. Protoc. Microbiol. 69,
A.1V.1–A.1V.8. doi: 10.1002/9780471729259.mc01a01s13
Civitelli, L., Panella, S., Marcocci, M. E., De Petris, A., Garzoli, S., Pepi, F.,
et al. (2014). In vitro inhibition of herpes simplex virus type 1 replication by
Mentha suaveolens essential oil and its main component piperitenone oxide.
Phytomedicine 21, 857–865. doi: 10.1016/j.phymed.2014.01.013
Counihan, N. A., Daniel, L. M., Chojnacki, J., and Anderson, D. A. (2006).
Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-
cytopathic and minimally cytopathic viruses. J. Virol. Methods 133, 62–69.
doi: 10.1016/j.jviromet.2005.10.023
De Chiara, G., Racaniello, M., Mollinari, C., Marcocci, M. E., Aversa, G.,
Cardinale, A., et al. (2016). Herpes simplex virus-type1 (HSV-1) impairs DNA
repair in cortical neurons. Front. Aging Neurosci. 8:242. doi: 10.3389/fnagi.2016.
00242
Elion, G. B. (1982). Mechanism of action and selectivity of acyclovir. Am. J. Med.
73, 7–13. doi: 10.1016/0002-9343(82)90055-9
Espy, M. J., Uhl, J. R., Mitchell, P. S., Thorvilson, J. N., Svien, K. A., Wold,
A. D., et al. (2000). Diagnosis of herpes simplex virus infections in the clinical
laboratory by LightCycler PCR. J. Clin. Microbiol. 38, 795–799.
Forghani, B., Dupuis, K. W., and Schmidt, N. J. (1985). Rapid detection of herpes
simplex virus DNA in human brain tissue by in situ hybridization. J. Clin.
Microbiol. 22, 656–658.
Guzman, C., Bagga, M., Kaur, A., Westermarck, J., and Abankwa, D.
(2014). ColonyArea: an imageJ plugin to automatically quantify colony
formation in clonogenic assays. PLoS ONE 9:e92444. doi: 10.1371/journal.pone.
0092444
Killington, R. A., and Powell, K. L. (1991). “Growth, assay and purification of
Herpes viruses,” in Virology a Practical Approach, ed. B. W. J. Mahy (Oxford:
IRL Press), 207–236.
Kruppenbacher, J. P., Kläss, R., and Eggers, H. J. (1994). A rapid and reliable
assay for testing acyclovir sensitivity of clinical herpes simplex virus isolates
independent of virus dose and reading time. Antiviral Res. 23, 11–22.
doi: 10.1016/0166-3542(94)90029-9
Kumar, P., Bartoszek, A. E., Moran, T. M., Gorski, J., Bhattacharyya, S., Navidad,
J. F., et al. (2012). High-throughput detection method for influenza virus. J. Vis.
Exp. 60:e3623. doi: 10.3791/3623
Langlois, M., Allard, J. P., Nugier, F., and Aymard, M. (1986). A rapid and
automated colorimetric assay for evaluating the sensitivity of herpes simplex
strains to antiviral drugs. J. Biol. Stand. 14, 201–211. doi: 10.1016/0092-
1157(86)90004-1
Maeda, N., Furukawa, A., Kakita, K., Anada, M., Hashimoto, S., Matsunaga, S.,
et al. (2016). Rapid screening by cell-based fusion assay for identifying novel
antivirals of glycoprotein b-mediated herpes simplex virus type 1 infection. Biol.
Pharm. Bull. 39, 1897–1902. doi: 10.1248/bpb.b16-00533
Matza-Porges, S., Eisen, K., Ibrahim, H., Haberman, A., Fridlender, B., and
Joseph, G. (2014). A new antiviral screening method that simultaneously detects
viral replication, cell viability, and cell toxicity. J. Virol. Methods 208, 138–143.
doi: 10.1016/j.jviromet.2014.08.007
Roizman, B., and Knipe, D. M. (2001). “Herpes simplex virus and their replication,”
in Fields Virology, eds D. M. Knipe and P. M. Howley (Philadelphia, PA:
Lippincott Williams and Wilkins), 2432–2434.
Safrin, S., Elbeik, T., and Mills, J. (1994). A rapid screen test for in vitro
susceptibility of clinical herpes simplex virus isolates. J. Infect. Dis. 169,
879–882. doi: 10.1093/infdis/169.4.879
Sarisky, R. T., Cano, R., Nguyen, T. T., Wittrock, R. J., Duffy, K. E., Clark, P., et al.
(2001). Biochemical characterization of a virus isolate, recovered from a patient
with herpes keratitis, that was clinically resistant to acyclovir. Clin. Infect. Dis.
33, 2034–2039. doi: 10.1086/338046
Tardif, K. D., Jorgensen, S., Langer, J., Prichard, M., and Schlaberg, R. (2014).
Simultaneous titration and phenotypic antiviral drug susceptibility testing for
herpes simplex virus 1 and 2. J. Clin. Virol. 61, 382–386. doi: 10.1016/j.jcv.2014.
08.015
Van der Beek, M. T., Claas, E. C., Van der Blij-de Brouwer, C. S., Morfin, F.,
Rusman, L. G., Kroes, A. C., et al. (2013). Rapid susceptibility testing for
herpes simplex virus type 1 using real-time PCR. J. Clin. Virol. 56, 19–24.
doi: 10.1016/j.jcv.2012.09.004
Verano, L., and Michalski, F. J. (1990). Herpes simplex virus antigen direct
detection in standard virus transport medium by Du Pont Herpchek enzyme-
linked immunosorbent assay. J. Clin. Microbiol. 28, 2555–2558.
Weldon, S. K., Mischnick, S. L., Urlacher, T. M., and Ambroz, K. L. (2010).
Quantitation of virus using laser-based scanning of near-infrared fluorophores
replaces manual plate reading in a virus titration assay. J. Virol. Methods 168,
57–62. doi: 10.1016/j.jviromet.2010.04.016
Zhu, Q. C., Wang, Y., and Peng, T. (2010). Herpes simplex virus (HSV) immediate-
early (IE) promoter-directed reporter system for the screening of antiherpetics
targeting the early stage of HSV infection. J. Biomol. Screen. 15, 1016–1020.
doi: 10.1177/1087057110372804
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Fabiani, Limongi, Palamara, De Chiara and Marcocci. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 8 June 2017 | Volume 8 | Article 1085
